Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Search
Global Careers Page | Boehringer Ingelheim
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US
Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.
STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US
Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Ryan Henri Rickards
Ryan Henry Rickards, a senior finance manager for US Animal Health Commercial Controlling team, highlights his career at Boehringer Ingelheim.
Press Material
Find the latest press releases from Boehringer Ingelheim on animal health or access our media pool to view BI corporate news.
Boehringer welcomes 2023 Gold Report
Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US
Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US
FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Management Rotation | Academic Programs
Management Rotation Program
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
Boehringer inhalers now available at $35 a month for eligible patients
Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients
Boehringer Ingelheim Subsidiaries and Affiliate Companies
Boehringer Ingelheim Subsidiaries and Affiliate Companies
World Water Day 2019 | Boehringer Ingelheim US
Click here to find out more on the steps Boehringer Ingelheim are taking on World Water Day 2019 to support animal shelters in Mexico City.
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap
Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia